The North Carolina facility produces complex APIs and intermediates in batch sizes from milligrams to 100kg to support clinical trials from Phase I to Phase III.
According to the company, the $2.4m investment will increase the site's reactor capacity by around 30%. The new 400 sq. ft. suite, which is expected to be operational in early 2018, will feature two 2,000-liter reactors and a 0.6 sq. m. Hastelloy filter dryer.
“We fill capacity whenever the market is asking for that and the market is good at the moment, especially I think for western-based CMOs,” Stephan Haitz, Ph.D., VP sales and business development at Cambrex told us at CPhI North America in Philadelphia this week.
As part of a second investment at the 35,000 sq. ft. site, previously PharmaCore, Inc., Cambrex is also upgrading its analytical chromatography data systems for QC and analytical R&D to new, Empower 3 software.
The upgrade will be introduced in Q3 and Q4 of 2017.
“Our clear focus was always manufacturing, but you need to bring a product to manufacturing, and hence with PharmaCore, we have the ability to start earlier,” said Haitz.
“You need to know the market but you [also] need to have a very close relationship with customers,” he added. “Our strategy is to grow with our customers in the market, and we’re a big fan of doing it organically.”